Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Accutane Pregnancy Exposure May Have Increased Under Risk Management Plan, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

During the first year of the SMART program, there were 120 pregnancy exposures, compared to 127 in the year prior to implementation of Roche's enhanced risk management program. The 23% decrease in prescriptions for the severe acne treatment suggests a relative increase in exposure.

You may also be interested in...

Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey

FDA advisory committee suggests  enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.

BI Finds Right Fit For Digital Therapeutic Partnership With Click

Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts